Trial Profile
A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Treatment of Metachromatic Leukodystrophy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Mar 2023
Price :
$35
*
At a glance
- Drugs Atidarsagene autotemcel (Primary) ; Busulfan
- Indications Metachromatic leukodystrophy
- Focus Adverse reactions; Therapeutic Use
- Acronyms TIGET-MLD
- Sponsors GlaxoSmithKline; GSK; Orchard Therapeutics
- 24 Feb 2023 According to an Orchard Therapeutics media release, data of this trial used for Long-term integrated analysis are being presented at the ongoing 19th Annual WORLDSymposium™ taking place February 22-26, 2023, in Orlando, Florida.
- 24 Feb 2023 Long-term results of updated integrated analysis in early-onset MLD patients enrolled in two prospective non-randomized clinical studies (n=30) or treated under expanded access frameworks (n=9) presented in an Orchard Therapeutics media release
- 04 Nov 2022 Planned End Date changed from 9 Apr 2023 to 15 Mar 2025.